ArriVent and Alphamab Partner on Multi-Target ADC

ArriVent BioPharma, Inc., a clinical-stage company focused on advancing innovative biopharmaceutical therapeutics, has entered into a strategic partnership with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a subsidiary of Alphamab Oncology. This collaboration is aimed at discovering, developing, and commercializing new antibody drug conjugates (ADCs) to treat cancer. The agreement, announced on June 5, 2024, will integrate Alphamab's ADC research and discovery platform with ArriVent's global development and commercialization expertise.

Bing Yao, Chairman and CEO of ArriVent, expressed excitement about the collaboration, stating that the partnership strengthens their pipeline with multiple innovative ADC programs. He emphasized the strategic model of identifying and developing first-and-best-in-class product candidates globally. Yao highlighted the potential of combining Alphamab’s research capabilities with ArriVent’s global drug development and commercialization expertise to address unmet needs in cancer treatment.

Ting Xu, Ph.D., Founder, Chairman, and CEO of Alphamab Oncology, echoed this enthusiasm. He noted that ArriVent shares Alphamab's commitment to developing differentiated and clinically valuable drugs. Xu pointed out that the collaboration leverages Alphamab's proprietary glycan-conjugation platform and ArriVent's oncology expertise to bring important new oncology therapeutics to patients worldwide.

The agreement specifies that both companies will utilize Alphamab's proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for cancer treatments. ArriVent will hold exclusive rights to develop and commercialize these ADCs globally, except for the regions of greater China, which include mainland China, Hong Kong, Macau, and Taiwan. In these areas, Alphamab retains the development and commercialization rights.

Financial terms of the arrangement include upfront and milestone payments to Alphamab, which could amount to a total of $615.5 million, contingent upon meeting specific regulatory, development, and sales milestones. Additionally, ArriVent will pay tiered sales royalties to Alphamab for each ADC product.

ArriVent is committed to identifying, developing, and commercializing differentiated medicines to address the unmet medical needs of cancer patients. The company aims to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, including next-generation ADCs, through approval and commercialization processes.

Alphamab Oncology is a biopharmaceutical leader in China, with a comprehensive proprietary biologics platform specializing in bispecific and protein engineering. Alphamab’s pipeline features monoclonal antibodies, bispecific antibodies, and ADCs in various stages of development, with one already approved for marketing by China's National Medical Products Administration and three others in late clinical stages. The company has developed several technologies and platforms for antibody-based cancer therapies, leveraging its proprietary protein engineering and structure-guided molecular modeling expertise to create multifunctional biological drug candidates for global patient benefit.

This partnership between ArriVent and Alphamab represents a significant step in the fight against cancer, combining cutting-edge research with extensive development and commercialization expertise to bring innovative treatments to patients in need.